Skip to main content
. Author manuscript; available in PMC: 2014 Sep 2.
Published in final edited form as: Lancet. 2011 Sep 9;378(9802):1547–1559. doi: 10.1016/S0140-6736(11)61383-4

Figure 2. Mean carotid total vessel area and percent increase in average carotid total vessel area (by MRI).

Figure 2

(A) Raw mean data (90% CI) for total vessel area at baseline, 6, 12, and 24 months. Total vessel area increased after 24 months in the placebo group: model-derived, corrected average absolute change (24 months–baseline) was 5·72 mm2 (90% CI 3·30–8·14), p=0·0002. However, in the dalcetrapib group, total vessel area did not change in the same period (1·71 [–0·68 to 4·10], p=0·24). The average reduction in total vessel area on dalcetrapib (versus placebo), after correction of baseline, was −4·01 (−7·23 to −0·80), p=0·04. (B) Group mean data for percent change in total vessel area at 6, 12, and 24 months (relative to baseline). In patients assigned placebo, model-derived, corrected total vessel area increased in the initial 24 months: percent change total vessel area was 10·8 (90% CI 5·8–15·8), p=0·001. However, in patients assigned dalcetrapib, total vessel area did not increase in the same period (4.0% [0.6–7·3], p=0·16). The average percent change in total vessel area in the dalcetrapib group (versus placebo), after correction of baseline, was −7·1% (−12·8 to −1·3), p=0·04.